Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 298
- Q1 2026, −28 vs. previous quarter
- 13F value
- $4.81B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $634.2M
- +20.0% year over year
- Net income, FY2025
- -$27.1M
- No comparable prior period
- Free cash flow, FY2025
- $29.8M
- No comparable prior period
- Revenue, Q4 FY2025
- $185.2M
- +23.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $27.1M (4.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Apr 15, 2026.
- Short interest
- 21.9M
- Shares sold short
- Change
- +824.6K
- +3.9% vs. previous
- Days to cover
- 7.48
- At average daily volume
Superinvestors holding FOLD, Q1 2026
Go to the superinvestors tab1 superinvestor reports holding Amicus Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.1%
Amicus Therapeutics, Inc.'s share of the portfolio
- Shares
- 5,753,186
- Value
- $83.2M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Amicus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Campbell Bradley LPresident and CEO | SSale | −22.5K | $14.35 | −$322.9K | −2.2%998.7K after | 10b5-1 |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Campbell Bradley LPresident and CEO | SSale | −75.0K | $14.31 | −$1.07M | −6.8%1.02M after | 10b5-1 |
| Dec 23, 2025 (view filing) | Dec 19 | 4 days | Clark David MichaelChief People Officer | SSale | −25.6K | $14.17 | −$363.3K | −9.5%245.7K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Campbell Bradley LPresident and CEO | SSale | −77.9K | $10.86 | −$846.3K | −6.5%1.13M after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Clark David MichaelChief People Officer | SSale | −25.6K | $11.00 | −$282.1K | −8.6%271.3K after | 10b5-1 |
| Dec 3, 2025 (view filing) | Dec 1 | 2 days | Campbell Bradley LPresident and CEO | SSale | −14.6K | $10.01 | −$146.0K | −1.3%1.14M after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Castelli JeffChief Development Officer | SSale | −76.2K | $10.16 | −$773.8K | −14.8%439.3K after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Clark David MichaelChief People Officer | SSale | −25.6K | $10.10 | −$259.0K | −7.9%297.0K after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24 | 2 days | Campbell Bradley LPresident and CEO | SSale | −14.6K | $10.04 | −$146.5K | −1.3%1.14M after | 10b5-1 |
| Nov 26, 2025 (view filing) | Nov 24-26 | 2 days | Rosenberg EllenChief Legal Officer | SSale | −95.6K | $10.02 | −$958.4K | −15.8%507.7K after | 3 lots10b5-1 |
Top 10 13F holders, Q1 2026
See all 298 holdersThe largest institutional positions in Amicus Therapeutics, Inc. at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 33,879,048 | $489.9M | 0.01% | +1,354,667+4.2% | Added |
| UBS Group AG | 15,957,913 | $230.8M | 0.04% | +10,064,625+170.8% | Added |
| Vanguard Capital Management LLC | 14,023,557 | $202.8M | 0.01% | +14,023,557 | New |
| Pentwater Capital Management LP | 14,000,000 | $202.4M | 1.44% | +2,500,000+21.7% | Added |
| Vanguard Portfolio Management LLC | 13,974,932 | $202.1M | 0.01% | +13,974,932 | New |
| State Street Corp | 12,893,897 | $186.4M | 0.01% | −1,939,417−13.1% | Reduced |
| Glazer Capital, LLC | 12,722,749 | $184.0M | 3.91% | +11,118,961+693.3% | Added |
| FIL Ltd | 12,560,028 | $181.6M | 0.14% | +11,603,028+1,212.4% | Added |
| Goldman Sachs Group Inc | 11,556,008 | $167.1M | 0.02% | +5,413,052+88.1% | Added |
| Qube Research & Technologies Ltd | 8,809,340 | $127.4M | 0.18% | +4,374,661+98.6% | Added |
Holders of 5% or more of FOLD
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Amicus Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.40%22.8M shares | −1.90 ppfrom 9.30% | Feb 5, 20252 filings | Apr 23, 2025 | SEC |
| Barclays PLC | 13G | 5.65%17.8M shares | New | May 14, 20261 filing | May 14, 2026 | SEC |
| UBS Group AG | 13G | 5.50%17.1M shares | New | May 7, 20261 filing | May 7, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.20%16.4M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in FOLD1 member of Congress reported 1 trade in Amicus Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 19, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · NY · May 19, 2023
Sell$1K-$15K